Make Your Voice Heard: Join the Call to Action for PN Advocacy!

Help Advocate for Government Funding for Peripheral Neuropathy Research in 2025

Due to the Foundation for Peripheral Neuropathy’s (FPN) advocacy efforts on the Hill, and countless letters from PN patients like you, Congress designated peripheral neuropathy as a condition in the Peer Reviewed Medical Research Program (PRMRP) in the annual Defense Appropriations Act during fiscal years 2021 through 2024. We need your help again for 2025.

During the last four years, the Department of Defense funded more than $13 million in peripheral neuropathy research! Year after year, peripheral neuropathy patients play a crucial role in advancing FPN’s advocacy mission by engaging with their federal government representatives. By writing letters urging for support and funding, patients serve as vital advocates, ensuring that the needs and challenges of the neuropathy community are heard and addressed on a legislative level.

Please see below on how you can help ensure “peripheral neuropathy” is renewed during the fiscal year 2025 appropriations process.

What You Can Do to Help Advocate

Contact the office of your U.S. senators and ask that they support “peripheral neuropathy” as a condition eligible for study through the Department of Defense Peer-Reviewed Medical Research Program during the fiscal year 2025 appropriations process. A letter template and each U.S. Senator’s contact information are listed below in bullets #1 and #3 respectively.

How to do it:

  • Complete this letter with your PN story.
  • Include your mailing address in your letter to establish that you are a constituent of the state your senator represents.
  • Send the letter by email to your senators. You can find their emails and other contact information by clicking here.
  • Please share your correspondence with us by sending a copy of your communication to our government relations consultant, Mark Vieth, at [email protected]


Please contact us at the Foundation for Peripheral Neuropathy at [email protected] if you have any questions.

Leave a Comment